| Ernest Mario |
Ernest Mario is currently the Chief Executive Officer at ALZA Pharmaceuticals. He is also the Chairman at Soleno Therapeutics, Inc., American Foundation for Pharmaceutical Education, Orbus Therapeutics, Inc., Capnia, Inc., and TAXIS Pharmaceuticals, Inc. Additionally, he serves as a Director at Rutgers University Foundation, Gladstone Foundation (CA), Silver Bullet Therapeutics, Inc., and Metalmark Capital LLC. Dr. Mario was previously the Chairman & Chief Executive Officer at ALZA Corp., Glaxo Wellcome Plc, IntraBiotics Pharmaceuticals, Inc., Reliant Pharmaceuticals LLC, and Apothogen, Inc. He also held positions as the Deputy Chairman & Chief Executive Officer at Glaxo Holdings Plc and Chief Executive Officer at GlaxoSmithKline Services Unlimited. Dr. Mario has served as the Chairman at Chimerix, Inc. and Duke University Health System, Inc. He was an Independent Director at Celgene Corp. and Boston Scientific Corp. Dr. Mario has also been the Lead Independent Director at Pharmaceutical Product Development LLC and an Independent Director at VIVUS, Inc., Maxygen, Inc., Alexza Pharmaceuticals, Inc., Prestwick Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Inc., TARIS BioMedical LLC, Delpor, Inc., Tonix Pharmaceuticals, Inc., Kindred Biosciences, Inc., XenoPort, Inc., Eyenovia, Inc., and Amplitude Healthcare Acquisition Corp. He served as a Director at Celgene, Inc. Dr. Mario has held trustee positions at Duke University, the University of Rhode Island, and Rutgers State University of New Jersey. He is also an Executive Advisory Board Member at Linden Manager LLC and a Board Member at Catalytica, Inc. Dr. Mario received his graduate and doctorate degrees from the University of Rhode Island and his undergraduate degree from Rutgers State University of New Jersey. |
